Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations provide new insights on the increased therapeutic index for ...

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...

TORONTO--(BUSINESS WIRE)--Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody™, for a broad range of therapeutic areas, including ...

CERo Therapeutics Holdings, Inc. announced that it will present preclinical data for its lead compound, CER-1236, targeting ovarian cancer during the Spring Scientific meeting of the Society for ...

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...

Lead program from TriSTAR T cell engager platform targets Nectin-4, a clinically validated tumor antigen overexpressed across multiple solid tumors, including urothelial cancer, NSCLC, TNBC, and ...

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for ...

BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) ...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline ...

The MarketWatch News Department was not involved in the creation of this content. -- Initial Phase 1 data, recently published in Nature Communications, demonstrated clinical activity with no dose ...